There is a shifting paradigm ofSSc subsets, including biologic classification of SSc subsets and fully data-driven approaches to SScsubset classification, taking into consideration the needs of the SSc global community in the modernera and the ability to prognosticate patients with SSc.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Systemic sclerosis (SSc) is a heterogeneous disease with variability in autoantibody profiles, skin andinternal organ involvement, disease trajectory, and survival.
📊
Key Findings & Data:The ability to identify more homogeneoussubsets of SSc patients has informed patient care and been an essential aspect of SSc research.In this article, the historic evolution of subsetting systems in SSc are described including clinicallybased SSc subsetting systems, their utility, strengths, and limitations.
💡
Conclusion & Impact:There is a shifting paradigm ofSSc subsets, including biologic classification of SSc subsets and fully data-driven approaches to SScsubset classification, taking into consideration the needs of the SSc global community in the modernera and the ability to prognosticate patients with SSc.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Systemic sclerosis (SSc) is a heterogeneous disease with variability in autoantibody profiles, skin andinternal organ involvement, disease trajectory, and survival. The ability to identify more homogeneoussubsets of SSc patients has informed patient care and been an essential aspect of SSc research.In this article, the historic evolution of subsetting systems in SSc are described including clinicallybased SSc subsetting systems, their utility, strengths, and limitations. There is a shifting paradigm ofSSc subsets, including biologic classification of SSc subsets and fully data-driven approaches to SScsubset classification, taking into consideration the needs of the SSc global community in the modernera and the ability to prognosticate patients with SSc.
🔖
Cite This Article
MATUCCİ-CERİNİC, M., JOHNSON, S. R., HOOGEN, F. V. D., DEVEKANDAN, K., POPE, J. E. (2022). Systemic sclerosis: To subset or not to subset, that is the question. European Journal of Rheumatology, Cilt: 7 - Sayı: 3, 222–227. https://ajindex.com/articles/511516
Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: Results of a delphi consensus study from eular scleroderma trials and research group. Ann Rheum Dis 2011
[Crossref] 2. Barnett AJ, Coventry DA. Scleroderma. 1. Clinical features, course of illness and response to treatment in 61 cases. Med J Aust 1969
[Crossref] 3. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002
[Crossref] 4. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986
Goetz R, Berne M. The pathophysiology of progressive systemic sclerosis (generalised scleroderma) with special reference to changes in the viscere. Clin Proc 1945
Holzmann H, Sollberg S, Altmeyer P. [Classification of progressive systemic scleroderma]. Hautarzt 1987
[Crossref] 7. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr., et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988
LeRoy EC, Medsger TA, Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001
Maricq HR, Valter I. A working classification of scleroderma spectrum disorders: A proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 2004
S5-13. 10. Masi AT. Classification of systemic sclerosis (scleroderma): Relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol 1988
Rodnan GP, Jablonska S, Medsger TA. Classification and nomenclature of progressive systemic sclerosis. Clin Rheumatic Dis 1979
Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002
[Crossref] 13. Tuffanelli DL, Winkelmann RK. Diffuse systemic scleroderma. A comparison with acrosclerosis. Ann Intern Med 1962